Acquisition of hepatitis C virus in hemodialysis patients: A prospective study by branched DNA signal amplification assay

Fabrizio Fabrizi, Paul Martin, Vivek Dixit, Maria Brezina, Mary J. Cole, Silvia Gerosa, Mariam Mousa, Gary Gitnick

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Serological data indicate that hepatitis C virus (HCV) infection is very common among chronic hemodialysis (HD) patients. Circumstantial evidence suggests that hemodialysis per se is an important risk factor for this infection. We used a novel methodology, the branched DNA (bDNA) signal amplification assay, which is capable of detecting HCV RNA and of quantifying HCV viral load in serum, to prospectively determine the rate of acquisition of HCV infection in 274 anti-HCV-negative patients undergoing HD treatment in four hemodialysis units. Moreover, we used bDNA testing to analyze the dynamics of HCV acquisition among HD patients, a high-risk group for HCV infection with immune compromise conferred from uremia. Two patients were identified with de novo acquisition during 1 year of prospective bDNA testing. Thus, the HCV incidence was 0.73% per year. De novo acquisition of HCV infection was observed in the absence of identifiable parenteral risk factors. Both patients showed the same pattern of HCV acquisition: they underwent an initial viremic phase that was associated with an increase in alanine transaminase (ALT) activity and that preceded the anti-HCV seroconversion. This was followed by HCV RNA clearance and normalization of ALT activity. Anti-HCV positivity occurred 1 and 2 months after the ALT increase in the first and second patients, respectively. Although HCV incidence was low (0.73%), further research is warranted to set the optimal policy for eliminating the risk of nosocomial transmission of HCV in the HD setting. Our findings show the pattern of HCV acquisition in chronic HD patients and emphasize the need to screen the HD population for ALT measurement combined with anti-HCV testing for detecting hepatitis C. HCV RNA testing can identify HCV before seroconversion in individuals with deranged liver function tests. The acquisition of HCV in HD patients without identifiable risk is confirmed.

Original languageEnglish
Pages (from-to)647-654
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume31
Issue number4
StatePublished - Apr 1 1998
Externally publishedYes

Fingerprint

Branched DNA Signal Amplification Assay
Hepacivirus
Renal Dialysis
Prospective Studies
Virus Diseases
Alanine Transaminase
RNA

Keywords

  • ALT
  • bDNA assay
  • HCV incidence
  • HCV viremia
  • HD

ASJC Scopus subject areas

  • Nephrology

Cite this

Acquisition of hepatitis C virus in hemodialysis patients : A prospective study by branched DNA signal amplification assay. / Fabrizi, Fabrizio; Martin, Paul; Dixit, Vivek; Brezina, Maria; Cole, Mary J.; Gerosa, Silvia; Mousa, Mariam; Gitnick, Gary.

In: American Journal of Kidney Diseases, Vol. 31, No. 4, 01.04.1998, p. 647-654.

Research output: Contribution to journalArticle

Fabrizi, F, Martin, P, Dixit, V, Brezina, M, Cole, MJ, Gerosa, S, Mousa, M & Gitnick, G 1998, 'Acquisition of hepatitis C virus in hemodialysis patients: A prospective study by branched DNA signal amplification assay', American Journal of Kidney Diseases, vol. 31, no. 4, pp. 647-654.
Fabrizi, Fabrizio ; Martin, Paul ; Dixit, Vivek ; Brezina, Maria ; Cole, Mary J. ; Gerosa, Silvia ; Mousa, Mariam ; Gitnick, Gary. / Acquisition of hepatitis C virus in hemodialysis patients : A prospective study by branched DNA signal amplification assay. In: American Journal of Kidney Diseases. 1998 ; Vol. 31, No. 4. pp. 647-654.
@article{3cf0cf0567bd4a75a2d87c5ea5657e5c,
title = "Acquisition of hepatitis C virus in hemodialysis patients: A prospective study by branched DNA signal amplification assay",
abstract = "Serological data indicate that hepatitis C virus (HCV) infection is very common among chronic hemodialysis (HD) patients. Circumstantial evidence suggests that hemodialysis per se is an important risk factor for this infection. We used a novel methodology, the branched DNA (bDNA) signal amplification assay, which is capable of detecting HCV RNA and of quantifying HCV viral load in serum, to prospectively determine the rate of acquisition of HCV infection in 274 anti-HCV-negative patients undergoing HD treatment in four hemodialysis units. Moreover, we used bDNA testing to analyze the dynamics of HCV acquisition among HD patients, a high-risk group for HCV infection with immune compromise conferred from uremia. Two patients were identified with de novo acquisition during 1 year of prospective bDNA testing. Thus, the HCV incidence was 0.73{\%} per year. De novo acquisition of HCV infection was observed in the absence of identifiable parenteral risk factors. Both patients showed the same pattern of HCV acquisition: they underwent an initial viremic phase that was associated with an increase in alanine transaminase (ALT) activity and that preceded the anti-HCV seroconversion. This was followed by HCV RNA clearance and normalization of ALT activity. Anti-HCV positivity occurred 1 and 2 months after the ALT increase in the first and second patients, respectively. Although HCV incidence was low (0.73{\%}), further research is warranted to set the optimal policy for eliminating the risk of nosocomial transmission of HCV in the HD setting. Our findings show the pattern of HCV acquisition in chronic HD patients and emphasize the need to screen the HD population for ALT measurement combined with anti-HCV testing for detecting hepatitis C. HCV RNA testing can identify HCV before seroconversion in individuals with deranged liver function tests. The acquisition of HCV in HD patients without identifiable risk is confirmed.",
keywords = "ALT, bDNA assay, HCV incidence, HCV viremia, HD",
author = "Fabrizio Fabrizi and Paul Martin and Vivek Dixit and Maria Brezina and Cole, {Mary J.} and Silvia Gerosa and Mariam Mousa and Gary Gitnick",
year = "1998",
month = "4",
day = "1",
language = "English",
volume = "31",
pages = "647--654",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Acquisition of hepatitis C virus in hemodialysis patients

T2 - A prospective study by branched DNA signal amplification assay

AU - Fabrizi, Fabrizio

AU - Martin, Paul

AU - Dixit, Vivek

AU - Brezina, Maria

AU - Cole, Mary J.

AU - Gerosa, Silvia

AU - Mousa, Mariam

AU - Gitnick, Gary

PY - 1998/4/1

Y1 - 1998/4/1

N2 - Serological data indicate that hepatitis C virus (HCV) infection is very common among chronic hemodialysis (HD) patients. Circumstantial evidence suggests that hemodialysis per se is an important risk factor for this infection. We used a novel methodology, the branched DNA (bDNA) signal amplification assay, which is capable of detecting HCV RNA and of quantifying HCV viral load in serum, to prospectively determine the rate of acquisition of HCV infection in 274 anti-HCV-negative patients undergoing HD treatment in four hemodialysis units. Moreover, we used bDNA testing to analyze the dynamics of HCV acquisition among HD patients, a high-risk group for HCV infection with immune compromise conferred from uremia. Two patients were identified with de novo acquisition during 1 year of prospective bDNA testing. Thus, the HCV incidence was 0.73% per year. De novo acquisition of HCV infection was observed in the absence of identifiable parenteral risk factors. Both patients showed the same pattern of HCV acquisition: they underwent an initial viremic phase that was associated with an increase in alanine transaminase (ALT) activity and that preceded the anti-HCV seroconversion. This was followed by HCV RNA clearance and normalization of ALT activity. Anti-HCV positivity occurred 1 and 2 months after the ALT increase in the first and second patients, respectively. Although HCV incidence was low (0.73%), further research is warranted to set the optimal policy for eliminating the risk of nosocomial transmission of HCV in the HD setting. Our findings show the pattern of HCV acquisition in chronic HD patients and emphasize the need to screen the HD population for ALT measurement combined with anti-HCV testing for detecting hepatitis C. HCV RNA testing can identify HCV before seroconversion in individuals with deranged liver function tests. The acquisition of HCV in HD patients without identifiable risk is confirmed.

AB - Serological data indicate that hepatitis C virus (HCV) infection is very common among chronic hemodialysis (HD) patients. Circumstantial evidence suggests that hemodialysis per se is an important risk factor for this infection. We used a novel methodology, the branched DNA (bDNA) signal amplification assay, which is capable of detecting HCV RNA and of quantifying HCV viral load in serum, to prospectively determine the rate of acquisition of HCV infection in 274 anti-HCV-negative patients undergoing HD treatment in four hemodialysis units. Moreover, we used bDNA testing to analyze the dynamics of HCV acquisition among HD patients, a high-risk group for HCV infection with immune compromise conferred from uremia. Two patients were identified with de novo acquisition during 1 year of prospective bDNA testing. Thus, the HCV incidence was 0.73% per year. De novo acquisition of HCV infection was observed in the absence of identifiable parenteral risk factors. Both patients showed the same pattern of HCV acquisition: they underwent an initial viremic phase that was associated with an increase in alanine transaminase (ALT) activity and that preceded the anti-HCV seroconversion. This was followed by HCV RNA clearance and normalization of ALT activity. Anti-HCV positivity occurred 1 and 2 months after the ALT increase in the first and second patients, respectively. Although HCV incidence was low (0.73%), further research is warranted to set the optimal policy for eliminating the risk of nosocomial transmission of HCV in the HD setting. Our findings show the pattern of HCV acquisition in chronic HD patients and emphasize the need to screen the HD population for ALT measurement combined with anti-HCV testing for detecting hepatitis C. HCV RNA testing can identify HCV before seroconversion in individuals with deranged liver function tests. The acquisition of HCV in HD patients without identifiable risk is confirmed.

KW - ALT

KW - bDNA assay

KW - HCV incidence

KW - HCV viremia

KW - HD

UR - http://www.scopus.com/inward/record.url?scp=0031916989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031916989&partnerID=8YFLogxK

M3 - Article

C2 - 9531181

AN - SCOPUS:0031916989

VL - 31

SP - 647

EP - 654

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 4

ER -